iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 892 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR First-Line 177Lu-Dotatate Plus Octreotide LAR Significantly Extends PFS in Patients with... June 13, 2024 Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... January 5, 2021 Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended... February 18, 2025 Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival... December 8, 2020 Load more HOT NEWS Medicare Open Enrollment is Almost Here-What You Need to Know for... Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,... Inguinofemoral Radiotherapy Could Spare Patients with Vulvar Cancer and Sentinel Node... Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with...
